KING & SPALDING LLP for SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2016 | $30,000 | Replaced |
| 2nd Quarter - Amendment | Oct 4, 2018 | $30,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to inclusion of prescription drugs within Essential Health Benefit; H.R. 2646, Helping Families in Mental Health Crisis Act of 2015; S. 1945, Mental Health Reform Act of 2015; S. 2680, Mental Health Reform Act of 2016; and mental health coverage expansion
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL F DONOVAN | Senate Committees on Finance, Small Business, and Government Affairs |
| DAVID JOSEPH FARBER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.